Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240011/S007

Altaviva Tibial Neuromodulation System (Altaviva P7850N)

Medtronic Neuromodulation · Decision date Feb 6, 2026

FDA DECISIONP240011/S007

What did the FDA decide?

FDA records P240011/S007 as a supplement to PMA P240011, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 6, 2026.

FDA approval order statement

approval to implement process changes in the manufacture of the 90nm Integrated Circuit (IC) wafer components on behalf of an external supplier
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Feb 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P240011/S007
Regulatory pathway
PMA supplement
Product code
QPT
Decision code
OK30
Decision date
Feb 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.

Product code
QPT
FDA device class
3

For the original device and its historical approval scope, see PMA P240011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240011 · Original PMA

    Medtronic Altaviva System

  2. P240011/S001 · Related supplement

    Altaviva Implantable Neurostimulator

  3. P240011/S002 · Related supplement

    Altaviva Implantable Neurostimulator

  4. P240011/S004 · Related supplement

    Medtronic Altaviva System

  5. P240011/S007 received

    Application receipt date recorded by FDA.

  6. P240011/S007 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P240011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240011

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic NeuromodulationPMA approvalSep 18, 2025FDA
Medtronic NeuromodulationPMA supplementOct 17, 2025FDA
Medtronic NeuromodulationPMA supplementOct 21, 2025FDA
AltavivaP240011/S003
Medtronic NeuromodulationPMA supplementNov 26, 2025FDA
Medtronic NeuromodulationPMA supplementDec 19, 2025FDA
AltavivaP240011/S005
Medtronic NeuromodulationPMA supplementJan 14, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 12, 2026FDA
AltavivaP240011/S008
Medtronic NeuromodulationPMA supplementFeb 27, 2026FDA
AltavivaP240011/S011
Medtronic NeuromodulationPMA supplementMar 26, 2026FDA
AltavivaP240011/S012
Medtronic NeuromodulationPMA supplementApr 3, 2026FDA
AltavivaP240011/S013
Medtronic NeuromodulationPMA supplementMay 13, 2026FDA
AltavivaP240011/S014
Medtronic NeuromodulationPMA supplementJun 16, 2026FDA
AltavivaP240011/S010
Medtronic NeuromodulationPMA supplementJul 13, 2026FDA
AltavivaP240011/S015
Medtronic NeuromodulationPMA supplementAug 14, 2026FDA
AltavivaP240011/S016
Medtronic NeuromodulationPMA supplementSep 14, 2026FDA

Explore the linked device profile

Other records with product code QPT

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementSep 9, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 20, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMar 3, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Neuromodulation

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
7000 Central Ave. NE, Ms Rce480, Minneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records